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ABSTRACT 
Estradiol (E2) enhances muscle growth in a number of species; however, the mechanism 
by which E2 enhances muscle growth is not known. Treatment with 10 nM E2 stimulates 
proliferation and protein synthesis and inhibits protein degradation in cultured bovine 
satellite cells (BSC). This is particularly significant because satellite cells are the source 
of nuclei needed to support postnatal muscle fiber hypertrophy and are thus crucial in 
determining the rate and extent of muscle growth; however the mechanism responsible 
for these E2 induced effects is not clear.  Studies in other tissues have suggested that E2 
may stimulate proliferation by activating the G protein-coupled estrogen receptor 
(GPER)-1 (formerly known as G protein-coupled receptor 30).  Activation of GPER-1 
results in activation of matrix metalloproteinases which release heparin-binding 
epidermal growth factor (hb-EGF) from the cell membrane and released hb-EGF interacts 
with the Epidermal Growth Factor Receptor (EGFR) resulting in increased proliferation. 
As an initial step in determining if this mechanism is involved in the effects of E2 on 
bovine satellite cell cultures, we have shown that silencing EGFR expression utilizing a 
specific EGFR siRNA suppresses the ability of E2 to stimulate proliferation in BSC 
cultures. Additionally, treatment of BSC cultures with a specific MMP 2/9 inhibitor 
suppresses E2 stimulated proliferation (p < 0.05).  Finally, treatment of BSC cultures 
with G15 or G36 (specific GPER-1 antagonists) suppresses E2 stimulated proliferation (p 
< 0.05).  These data strongly suggest that E2 stimulated transactivation of EGFR via 
GPER-1 is at least partially responsible for E2 induced increases in proliferation in BSC 
cultures.  
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LITERATURE REVIEW 
Introduction 
The utilization of growth enhancing technologies, specifically anabolic steroids, is a very 
common management practice in the beef industry today.  According to the National 
Animal Health Monitoring System (NAHMS) (2000), 97% of feedlot cattle receive at 
least one steroid implant during their lifespan.  The utilization of implants results in a 
significant reduction in production costs, showing an increase in value of $93 per animal 
(1).  Growth enhancing technologies play a significant role in the increased efficiency of 
the beef industry, by streamlining the input of resources per unit of food produced.  The 
animals require less days on feed and are more efficient with the nutrients they receive, 
resulting in less feed required per unit of gain (2).  The effects of implants are far 
reaching, as in addition to increasing production efficiency and being economically 
beneficial they contribute to achieving the sustainability needs of the agricultural 
industry.  Implant usage contributes to a decrease in emission of greenhouse gases per 
unit of food due to fewer animals necessary to produce the same quantity of food (3).  
Animals receiving implants produce 31% less CH4 and N2O compared to non-implanted 
animals due to decreased days on feed and dry matter intake necessary to achieve market 
weight (4).  The use of growth enhancing technologies also contributes to sustainability 
by decreasing the land necessary to produce the same quantity of beef (2; 3).  
Implantation is a management practice that improves overall beef herd productivity and 
reduces the non-productive portion of the animal’s life.  There are many benefits to 
anabolic steroid implant use in the beef industry, however the mechanism that anabolic 
steroids utilize to enhance muscle growth is unknown.  This literature review will 
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concentrate on the estrogenic effects in a multitude of tissues and how they contribute to 
elucidating estrogen’s function in muscle growth.   
Anabolic Steroid Implants 
Steroid implants have been used as a beef management tool since the 1950s.  According 
to the Center for Veterinary Medicine there are currently thirty-eight different implant 
products available to beef producers.  Implants contain anabolic steroids that are slowly 
released over a period of time.  They can be utilized in either gender, for a broad age 
range of cattle, and at different stages of production.  The implants are either an 
estrogenic, androgenic, or combination of estrogenic and androgenic compounds.  The 
estrogenic options are the natural hormone estradiol (E2) or a synthetic compound 
zeranol.  There are eight available implants utilizing solely estrogenic activity.  The 
androgenic compounds contain either the natural hormone testosterone propionate or the 
synthetic compound trenbolone acetate (TBA).  There are only two available implants 
utilizing only androgenic activity.  TBA is more active than testosterone propionate and 
is more commonly utilized in implants.  There are twenty-eight implants that utilize a 
combination of estrogenic and androgenic activity (5).  Currently in the industry about 
two thirds of the implants used are trenbolone acetate (TBA) and estradiol (E2) 
combination implants (2).  The use of steroid implants as a management practice has 
been shown to increase efficiency of beef production.   
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Production Characteristics 
Steers that received a TBA/E2 combination implant in addition to other growth 
enhancing technologies have a decrease in cost per kilogram of body weight gained.  
Implanted steers cost producers $1.12 per kilogram of weight gained as compared to  
non-implanted steers that cost $1.35 per kilogram of weight gained (4).   Implants are 
most efficient during the first forty days after application as their benefits are most 
pronounced during that time period.  However, they are still functional for up to 115 days 
following initial implantation (6).  A TBA/E2 combination implant given to steers 
increases average daily gain (ADG) 18-36% and feed efficiency 8-34% over non-
implanted steers (1; 6-9).  In studies done in wethers a TBA/E2 implant induced an 
increase in ADG of 25% and in feed efficiency of 23% over non-implanted wethers (8).  
Estrogen alone increases feed intake as much as 12% (6).  During the period from 0 to 40 
days steers implanted with TBA/E2 exhibited an 82% increase in carcass protein 
accretion over control steers (6).  An increase in daily carcass protein accretion was also 
seen in wethers implanted with TBA/E2 (8).  The combination of TBA/E2 results in the 
greatest increase in protein accretion.  Steers receiving TBA/E2 displayed 25% more 
protein accretion than steers implanted with E2 and 60% over steers implanted with TBA.  
Correlating with protein accretion, body weight gain was greatest for steers implanted 
with TBA/E2, followed by steers given E2, and lastly steers treated with TBA (10).  
Implantation increased carcass weight 7% over non-implanted steers.  Although 
implantation has a positive impact upon production efficiency, it has an ambiguous 
impact upon carcass characteristics.  A review of implantation studies showed there was a 
7% decrease in fat cover, 5% decrease in marbling, and 17% decrease in carcasses 
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grading Choice or better (11).  The decrease in fat and marbling of the animal may be due 
to energy going towards increased muscle production and sustained muscle growth 
instead of achieving a muscle growth plateau that allows the energy to contribute to fat 
accretion.  Additionally, there are conflicting reports of implants resulting in higher 
Warner-Bratzler shear force values indicating that animals receiving implants have 
tougher meat (1).  However, based upon consumer panels there is no difference in 
palatability between implanted and non-implanted meat products (11). 
Role of Satellite Cells in Muscle Growth 
During embryonic muscle development multipotent stem cells experience differentiation 
and determination to form muscle precursor cells that are dedicated to forming muscle.  
Muscle precursor cells proliferate and after expression of myogenic regulatory factors 
muscle precursor cells further differentiate into mononucleated cells known as myoblasts.  
Myoblasts are unable to undergo proliferation; however they fuse with each other to form 
multinucleated myotubes that develop into muscle fibers found in mature muscle.  In 
meat-producing animals fiber formation is completed prior to birth.  Muscle fibers are not 
able to proliferate and their nuclei no longer have the ability to divide.  Consequently, the 
number of muscle fibers is fixed at birth and does not increase significantly during 
postnatal growth.  Due to the fact that muscle fiber number is fixed at birth, hypertrophy 
of muscle fibers is necessary for postnatal muscle growth.  In order to support postnatal 
muscle fiber hypertrophy, something crucial in the meat production industry, additional 
nuclei, beyond those present at birth, must be added to the muscle fiber in order to 
support critical cellular functions. However, since nuclei in the muscle fiber can no 
longer divide or undergo DNA synthesis, the new nuclei needed to maintain an 
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acceptable protein to DNA ratio and support muscle growth must come from outside the 
muscle fiber.  Mononucleated satellite cells found in the “satellite niche” located between 
the basement membrane and the sarcolemma of each fiber are the source of these nuclei 
needed to support postnatal muscle growth.  Satellite cells are very important as they 
contribute 60-90% of DNA present in muscle fibers of mature muscle (12).     
Moss and Leblond (1971) ascertained the contribution of satellite cells’ nuclei to muscle 
fibers during an in vivo study conducted in rats.  Rat muscle was injected with 
3
H-
thymidine and at 1 hour all of the labeled nuclei were in satellite cells.  There were no 
labeled nuclei in the muscle fiber confirming that the nuclei in the muscle fiber were not 
synthesizing DNA.  Twenty-four hours post-injection 15% of the labeled nuclei had 
fused with the true muscle fiber.  After 72 hours 65% of the labeled nuclei were 
incorporated in the muscle fiber, indicating that the satellite cells were fusing with muscle 
fiber, providing additional DNA (13).  Satellite cells are able to proliferate increasing 
their numbers or differentiate to fuse with existing muscle fiber providing nuclei needed 
for hypertrophy.  Whether they proliferate or differentiate is dependent upon the growth 
factor and hormone levels present in the satellite cell niche (14).  The number of satellite 
cells decreases during postnatal muscle growth as differentiation and fusion take 
precedence over proliferation.   
In newborn animals 30% of muscle nuclei are satellite cell nuclei.  As the animal ages, 
the amount of available satellite cell nuclei decreases to 2-10% of muscle cell nuclei (12) 
and the majority of the remaining satellite cells enter a quiescent phase (G0) in which 
they neither proliferate nor fuse with existing muscle fibers unless stimulated by exercise 
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or muscle injury.  As a result, the number of nuclei available to add to fibers to support 
hypertrophy required for normal muscle growth is greatly reduced resulting in plateauing 
of muscle growth. The importance of satellite cells in postnatal muscle growth is shown 
by studies in which satellite cell numbers are dramatically reduced by radiation or genetic 
manipulation.  Animals undergoing radiation or genetic manipulation exhibit postnatal 
muscle growth that is dramatically retarded (15; 16). 
Quiescent satellite cells are activated in response to stimuli such as exercise or injury.  
Satellite cells express Pax7 which enables them to undergo proliferation or 
differentiation.  Myogenic regulatory factors (MRFs) play an important role during 
embryonic development and their impact upon satellite cell activation is very similar to 
their effect on embryonic myogenic cells.  Myoblast determination protein (MyoD) and 
Myogenic Factor 5 (Myf5) expression result in the activation of satellite cells in the 
quiescent phase (16) and the satellite cells undergo proliferation.  Myoblasts produce 
myogenin and muscle-specific regulatory factor 4 (MRF4) which are necessary for 
myoblasts to undergo terminal differentiation and fuse into myotubes (16).  MRFs are 
important not only in the activation of quiescent satellite cells but also in determining 
whether satellite cells will undergo proliferation or differentiation.      
There are three facets that interact to achieve muscle growth; proliferation, protein 
synthesis and protein degradation.  Proliferation provides additional satellite cells that can 
either continue dividing or fuse with existing muscle fiber to provide DNA needed to 
support protein accretion.  Protein synthesis and protein degradation interact to result in 
protein accretion.  An increase in protein synthesis is and a reduction in protein 
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degradation is ideal for optimal protein accretion.  Skeletal muscle hypertrophy requires 
both increased protein accretion and increased nuclei number to support the additional 
protein present in the myofiber.  
Effect of a combined TBA/E2 implant on satellite cell number and activity 
As indicated in the previous section, satellite cells are necessary for postnatal muscle 
growth.  Determining the impact that anabolic steroids exhibit on satellite cells will help 
elucidate the pathway involved in anabolic steroid enhanced muscle growth.  Muscle 
from steers implanted with Revalor-S™ (an implant containing 120mg TBA and 24mg 
E2) contained 50% more satellite cells (7) than muscle from non-implanted steers.  
Additionally, cultured satellite cells from implanted animals exhibited greater 
proliferative response to growth factors such as  Insulin-like Growth Factor-1(IGF-1) and 
Fibroblast Growth Factor (bFGF)  than satellite cells from non-implanted animals (17).  
Satellite cell cultures isolated from TBA/E2 implanted steers contained 50% more 
myotube nuclei  than corresponding cultures isolated from non-implanted steers (7).   
Cultured satellite cells isolated from non-implanted steers had a longer lag phase prior to 
proliferation than satellite cells isolated from steers that received a TBA/E2 implant, 
indicating that a larger proportion of the satellite cells in non-implanted muscle was in a 
quiescent state (7).  These results indicate that implantation has an impact upon both 
satellite cell number and behavior.   
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TBA/E2 implant impact on muscle IGF-1 mRNA and IGF-1 serum levels 
The insulin-like growth factor system plays an important role in growth and development 
of numerous tissues and regulates overall growth.  The IGF system is composed of two 
IGF ligands, insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-II (IGF-
2).  Within the system there are three cell surface receptors that mediate IGF function, 
insulin-like growth factor receptor-1 (IGFR-1), insulin-like growth factor receptor 2 
(IGFR-2), and the insulin receptor (IR).  Additionally, the IGF system contains a family 
of six IGF-binding proteins that contribute to regulation of the IGF system by 
determining if IGF ligands are available to bind and activate the receptors (18).  IGF-2 is 
primarily expressed prenatally and decreases after birth (18).  In contrast IGF-1 
expression is low prenatally and increases significantly as an animal matures (18).  
Insulin-like growth factor -1 stimulates muscle growth by increasing muscle protein 
synthesis rate (19) and decreasing muscle protein degradation rate (19).  Additionally, 
IGF-1 stimulates proliferation and differentiation of muscle satellite cells.  Consequently, 
adequate levels of IGF-1 are crucial to muscle growth.  
Based on the positive effects of IGF-1 on muscle growth, it is significant that serum 
levels of IGF-1 were increased by anabolic steroid implantation.  By day 6 steers 
implanted with TBA/E2 (Revalor-S™) exhibited an increase in serum IGF-1 of 32% over 
non-implanted steers and sustained the higher level for the 32 day trial (7).  An additional 
study supported the impact of TBA/E2 upon serum IGF-1 levels; reporting that  by days 
14 and 28 there was a 53% and 85% increase, respectively, in serum IGF-1 levels in 
implanted steers over non-implanted steers (20).  Steers receiving a TBA/E2 implant 
exhibited a 54% increase in serum IGF-1 over their pre-implant IGF-1 levels (20).   
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Due to the fact that the majority of circulating IGF-1 is synthesized in the liver, the effect 
of steroid implantation on liver IGF-1 mRNA expression was measured.  Steers given a 
TBA/E2 combination implant exhibited a 69% increase in hepatic IGF-1 mRNA level 
(9).  Wethers implanted with TBA/E2 showed a 150% increase in hepatic IGF-1 mRNA 
levels (8).  This indicates that the increase in IGF-1 mRNA levels in the liver contributes 
to increased circulating IGF-1 levels in Revalor-S™ implanted steers.   
However, the role of circulating IGF-1 in stimulating muscle growth is controversial 
because growth rates are not significantly impacted in rats in which liver IGF-1 
production has been knocked out (21).  In contrast, studies in mice overexpressing IGF-1 
in muscle have shown that increased production of IGF-1 in muscle stimulates muscle 
growth via autocrine/paracrine mechanisms (22).  Consequently, muscle IGF-1 mRNA 
expression in Revalor-S™ implanted steers was examined.  Twenty-six days after 
implantation with Revalor-S™ steers exhibited longissimus muscle IGF-1 mRNA levels 
3 times higher than on day 0 (9).  Additionally, Revalor-S™ implanted steers exhibited 
94% higher IGF-1 mRNA levels than non-implanted steers (9). Based on studies showing 
that overexpression of IGF-1 mRNA in muscle increases muscle growth rate (22), it 
appears likely that the increased IGF-1 mRNA levels in muscle of implanted steers plays 
a significant role in anabolic steroid induced muscle growth.   
In order to examine the individual roles of TBA and E2 in Revalor-S™ stimulated 
muscle growth, steers were implanted with either TBA or E2 at the dosage present in the 
Revalor-S™ implant.   Biopsies of the longissimus muscle showed that steers implanted 
solely with E2 exhibited an increase in IGF-1 mRNA levels by day 7 (23) and ultimately 
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expressed 71% higher levels of IGF-1 mRNA than steers that were not implanted (23).  
Steers implanted with TBA exhibited the same IGF-1 mRNA levels as steers that were 
not implanted (23).   
Effects and mechanism of action of Estrogen in non-muscle systems 
Estrogen is involved in a variety of body systems and functions including reproduction, 
immune, nervous, cardiovascular, and cancer and its physiological effects include 
growth, development, and homeostasis of a multitude of tissues.  Additionally, E2 has 
been shown to stimulate proliferative activity in breast, uterus, tumor and non-tumor cells 
(24-26).  The mechanism of E2 action in these non-muscle tissues has been extensively 
studied and results of these studies provide information about the potential mechanism of 
E2 enhance muscle growth in cattle. Consequently, in this section I will review the 
mechanism of action of E2 in a variety of non-muscle body systems.   
Classic Estrogen receptor mechanism of action 
Estrogen has two classical receptors, ER-α identified in the 1970’s and ER-β identified in 
the mid 1990’s.  These two classical receptors interact with E2 and are responsible for 
some of the effects that E2 exhibits on cell function, especially the genomic effects (27).  
While ER-α and ER-β can move between the nucleus and cytoplasm the majority are 
found in the nucleus with ~5% found in the cytoplasm (28).  Classical estrogen receptors 
can be activated in several ways. They can function as ligand-activated nuclear 
transcription factors producing genomic effects.  Secondly, classical estrogen receptors 
may be activated in the cytoplasm through phosphorylation or other post-transcriptional 
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modifications producing rapid non-genomic effects (29).  ER-α is the predominate 
estrogen receptor in most tissues (30).   
Role of Epidermal Growth Factor Receptor (EGFR) in E2 action 
E2 rapidly stimulates Epidermal Growth Factor Receptor (EGFR) activation in cancer 
cells (31; 32).  Epidermal Growth Factor Receptor (EGFR) is a 170kDa tyrosine kinase 
receptor that is activated after binding with ligands such as Epidermal Growth Factor 
(EGF) or heparin-binding Epidermal Growth Factor (hb-EGF).  Activation of EGFR 
ultimately results in DNA synthesis and cell proliferation.  In MCF-7 breast cancer cells 
and COS-7 cells E2 and IGF-1 treatment increased phosphorylation of EGFR while not 
to the extent observed in cells treated with  EGF (33).  A specific EGFR tyrosine kinase 
inhibitor AG1478, which binds to the receptor and distorts its shape rendering it 
incapable of proper function, inhibited IGF-1 induced phosphorylation of EGFR in Rat-1, 
human embryonic kidney, and breast cancer cells (33; 34).  AG1478 inhibited the 
phosphorylation of EGFR without reducing levels of EGFR protein in CNE2 cells (35).  
The lack of change in protein levels indicate that AG1478 inhibition happens at a post-
translational level.  In addition to affecting EGFR phosphorylation, AG1478 also 
inhibited serum induced cell proliferation of CNE2 nasopharyngel carcinoma cells (35).  
To further support the results from the AG1478 studies, knockdown of the EGFR with a 
siRNA suppressed the stimulation of proliferation induced by E2, IGF-1, and EGF (34; 
36-38) in COS-7 and MCF-7 cancer cells.  This accumulation of data conveys that 
suppression of EGFR also suppresses ER-α and IGFR-1 activity.   This supports the 
model that EGFR is the downstream converging point for ER-α and IGFR-1 action. 
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 Role of G protein–coupled estrogen receptor (GPER)-1 in E2 action 
Rapid estrogen action is not completely dependent on ER-α and ER-β as indicated by the 
fact that it takes place in SKBR3 breast cancer cells that lack mRNA for both of the 
classical receptors (39).  Additionally, in ER-α and ER-β knockout mice there was still a 
response to estrogen.  Further investigation revealed that  G protein-coupled estrogen 
receptor (GPER)-1 was mediating estrogen function in these mice (28).   
Numerous reviews of E2 action in non-muscle tissues and cancer cells have shown that, 
in addition to ER-α and ER-β, the G protein-coupled estrogen receptor (GPER)-1 
contributes to rapid non-genomic estrogen response in numerous tissues (40; 41).  These 
studies have shown that binding of E2 to GPER-1 results in transactivation of the 
Epidermal Growth Factor Receptor (EGFR) (28; 33; 34; 40; 42; 43).  GPER-1 
(previously known as G protein-coupled receptor 30 (GPR30)) is a member of the G-
protein-coupled receptor (GPCRs) family which is the largest known family of signaling 
molecules with 900 members (41).  GPER-1 is a seven transmembrane spanning receptor 
expressed on the cell surface.  Estrogen binds to GPER-1 with high affinity and that 
binding activates GPER-1 releasing the Gβγ protein complex (44).  These subunits of the 
GPER-1 stimulate the activity of matrix metalloproteinases (MMP) 2/9.  Matrix 
metalloproteinase 2 and matrix metalloproteinase 9 are members of a family of zinc-
dependent proteases.  MMPs enable the proteolytic cleavage and release of heparin-
binding Epidermal Growth Factor (hb-EGF) from the cell surface.  Heparin-binding 
Epidermal Growth Factor is a peptide ligand in the EGF family.  The cleaved hb-EGF is 
able to bind to Epidermal Growth Factor Receptor (EGFR) resulting in EGFR 
13 
 
transactivation which mediates downstream pathways, including the MAP kinase 
pathway (28; 33; 34; 40; 42; 43) which regulates proliferation and protein synthesis.  
GPER-1 transactivation of EGFR is crucial for the rapid, non-genomic response to E2 in 
cells.   
The E2/GPER-1 mechanism of action is further supported by the following compilation 
of literature.  Tamoxifen and ICI 182,780 are ER antagonists that exhibit a very high 
affinity for classical ERs and compete with E2 for a binding site resulting in inhibition of 
E2 stimulation.  Surprisingly, treatment of COS-7 and MCF-7 breast cancer cells with 
these antagonists resulted in increased proliferation. Further studies revealed that in 
addition to binding to and inhibiting ER-α and ER–β activity, ICI 182,780 and tamoxifen 
are also able to bind to GPER-1; however, they function as GPER-1 agonists in bone and 
other tissues resulting in stimulation of activity instead of an inhibition of activity (28; 
40; 42; 45-47).  Treatment of MCF-7 breast cancer cells with these ER antagonists 
resulted in an increase in GPER-1 expression, and GPER-1 mediated EGFR 
phosphorylation (28; 40) resulting in increased proliferation.  Consequently, it is likely 
that E2 binding to GPER-1 also results in increased proliferation rates via transactivation 
of EGFR.  
The fact that E2 activates both the classical E2 receptors (ER-α and ER-β) as well as 
GPER-1 has presented a significant problem in defining the function of each class of 
receptor.  However, the relatively recent discovery of two GPER-1 specific antagonists 
and an agonist that do not affect the activity of the classical E2 receptors has made it 
possible to study the role of GPER-1 independently of the classical E2 receptors.  This 
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has led to additional research defining the complex relationship between estrogen and 
GPER-1.  Both G15 and G36 are GPER-1 specific antagonists.  The GPER-1 specific 
agonist, G1 has been found to weakly bind to ER at very high concentrations as does G15 
(46).  In uterine epithelial cells G1 stimulates proliferation and blocking GPER-1 with 
G15 reduced E2 induced proliferation by 50% (28).  These results indicate that activation 
of GPER-1 may stimulate proliferation.  Additionally, treatment of breast cancer cells 
and primary mouse mammary epithelial cells with a GPER-1 agonist leads to EGFR 
phosphorylation (48).  When cells were treated with AG1478 (EGFR tyrosine kinase 
inhibitor), EGFR phosphorylation was inhibited resulting in a suppression of GPER-1 
mediated mitogenic signaling in the ERK/MAP kinase pathways (44).  This indicates that 
functional EGFR is necessary for GPER-1 activity.  GPER-1 mediated EGFR 
phosphorylation was inhibited when MMP2/9 were inhibited, indicating that MMP2/9 are 
required in order for GPER-1 to stimulated EGFR phosphorylation (48).  When the 
MMPs are inhibited the amount of proteolytically cleaved and free hb-EGF is reduced, 
indicating that MMPs are necessary for GPER-1 mediated release of hb-EGF, a crucial 
aspect of EGFR transactivation (42; 49; 50).  The reduction in hb-EGF resulted in the 
EGFR phosphorylation being suppressed (42; 49; 50).  In a breast cancer cell line 
overexpression of GPER-1 resulted in transactivation of EGFR via release of hb-EGF 
(48).  These data support the hypothesis that receptor cross-talk between GPER-1 and 
EGFR involves both MMP2/9 and hbEGF and  is responsible for various important 
biological functions such as gene expression and cancer cell proliferation  (49). 
Potential role of IGF-1 and IGFR-1 in E2 mechanism of action 
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Insulin-like Growth Factor-1 (IGF-1) is a member of the insulin-like growth factor 
system which plays an important role in growth and development in most organs and 
tissues.  ER-α regulates the IGF-1 pathway and in turn IGF-1 activates ER-α mediated 
signaling in a ligand independent manner (49).  Insulin-like Growth Factor Receptor-1 
(IGFR-1) is an 180kDa receptor that contains two α-subunits and two β-subunits.  
Insulin-like Growth Factor Receptor-1α (IGFR-1α), is a 85kDa subunit that is the 
extracellular portion of the IGFR-1 and the section that binds to IGF-1 (51).  Insulin-like 
Growth Factor Receptor-1β (IGFR-1β), is a 95kDa subunit that crosses the cell 
membrane and contains the tyrosine kinase portion of the IGFR-1 (51).  IGF-1 binding to 
IGFR-1 results in activation of the tyrosine kinase which begins a cascade of 
phosphorylation in other receptors.  IGF-1 and IGFR-1 may be involved in the role of 
non-genomic E2 rapid response in cells.  In breast and endometrial cancer cells, 
osteoblastic cells, and rat muscle cells E2 up regulated IGF-1 mRNA levels; however, 
treatment with ICI 182,780 (ER antagonist) inhibited the up regulation of IGF-1 mRNA 
levels (24; 25; 52).  This indicates that functioning ER is involved in IGF-1 mRNA 
expression.    
To further elucidate IGF/IGFR-1 role within different tissues AG1024, a specific 
inhibitor, was developed.  AG1024 is a member of the tyrophostin family which is a 
family of synthetic protein tyrosine kinase inhibitors that inhibit receptor 
autophosphorylation.  IGFR-1 is a member of the tyrosine kinase receptor family 
therefore functional tyrosine kinase of IGFR-1 is necessary for signaling function of the 
receptor.  Although AG1024 is specific for IGFR-1β tyrosine kinase inhibition, due to the 
fact that the structure of the insulin receptor and IGFR-1 are quite homologous, AG1024 
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also is able to inhibit the insulin receptor tyrosine kinase although to a lesser degree than 
it inhibits the IGFR-1 tyrosine kinase  (53).  AG1024 resembles the phenolic group of 
tyrosine allowing AG1024 to compete effectively with IGF-1 for binding to IGFR-1.  
Following binding of AG1024 to IGFR-1 the receptor is distorted so it is incapable of 
autophosphorylation and the receptor is rendered non-functional (53).  IGF-1 stimulates 
the phosphorylation of IGFR-1 and proliferation but those effects are abrogated by 
AG1024 (53). Treatment of MCF-7 breast cancer cells with AG1024 in addition to IGF-1 
resulted in suppression of IGF-1 stimulation of EGFR phosphorylation (36; 37). 
Similarly, E2 stimulates IGFR-1 phosphorylation (30) and treatment of cells with 
AG1024 prevents that phosphorylation.  This indicates that functional IGFR-1 is essential 
for both E2 and IGF-1 stimulated proliferation.  In mouse fibroblast cells and MCF-7 
breast cancer cells EGF did not stimulate phosphorylation of the IGFR-1, nor was its 
proliferative effects inhibited by AG1024 (36; 37; 53).  Additionally, both IGF-1 and 
EGF were able to cause phosphorylation of EGFR (33) in COS-7 cells.  Studies showing 
that IGF-1 is able to stimulate EGFR but EGF is not able to stimulate IGFR-1 suggest 
that EGFR is downstream of the IGFR-1.  In breast cancer cells knockdown of IGFR-1 
with siRNA did not impact expression of EGFR however it did suppress E2 stimulated 
phosphorylation of EGFR and E2-stimulated proliferation (31; 32).  This implies that E2 
stimulation of EGFR was mediated by IGFR-1.  Studies on IGFR-1 silenced cells 
supported the conclusions of the AG1024 data showing that  IGF-1 and E2 stimulated 
phosphorylation of EGFR and proliferation require functional IGFR-1 (51).  This would 
support the theory that the IGFR-1 and EGFR are both part of the E2 pathway with 
EGFR being downstream of the IGFR-1.   
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Effects of Estrogen on muscle satellite cells in vitro 
As described in the preceding section, the mechanism of estrogen action has been studied 
in a variety of non-muscle cells and systems.  However, despite the fact that estrogen 
plays a crucial role in stimulating and sustaining postnatal muscle growth little 
information is available on the mechanism involved in E2 enhanced muscle growth in the 
bovine.  However, recent in vivo studies have shown that an E2 stimulated increase in 
satellite cell proliferation may play a significant role in E2 enhanced muscle growth in 
the bovine. Consequently, elucidating the mechanism involved in E2 enhanced satellite 
cell proliferation should provide valuable information on the mechanism of E2 enhanced 
muscle growth.  Bovine satellite cell culture provides a controlled environment that 
allows us to study the mechanism of E2 enhanced satellite cell proliferation.  
Estrogen effect on IGF-1 expression in cultured BSC 
As described previously, IGF-1 is a growth factor that plays an important role in growth 
and development.  IGF-1 is locally produced in skeletal muscle and animals that 
overexpress IGF-1 in muscle show an increase in muscle hypertrophy and overall muscle 
mass (54).  Consequently, it is significant that recent studies have shown that E2 
implantation increases IGF-1 mRNA expression in bovine skeletal muscle (8). Due to 
bovine satellite cells  grown in cell culture being able to produce IGF-1 and release it into 
the media, mimicking the action of skeletal muscle IGF-1 production in vivo (55), bovine 
satellite cell culture provides a controlled environment in which to study the mechanism 
involved in E2-stimulated IGF-1 mRNA expression.  
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In media containing 10% fetal bovine serum (FBS), Estrogen treatment stimulated IGF-1 
mRNA levels in cultured bovine satellite cells (BSCs) in a concentration dependent 
manner.  IGF-1 mRNA level was 1.9 times higher in BSC cultures treated with 0.01nM 
E2 over control cells.  IGF-1 mRNA levels were up to 3.5 times higher in BSCs treated 
with 1nM E2 than in control BSCs (56).  Treatment of cells with E2-BSA (E2-BSA is not 
able to enter the cell so in order to express an effect it must bind to a cell surface 
receptor) resulted in a 100% increase in IGF-1 mRNA (57).  As ~95% of ER is located in 
the nucleus this indicates that E2 is not stimulating IGF-1 mRNA expression by binding 
to ER-α but rather by interacting with a cell surface receptor such as GPER-1.  
Additionally, ICI 182,780 (ER antagonist) was not able to inhibit the E2 stimulation of 
IGF-1 mRNA and actually resulted in a 93% increase in IGF-1 mRNA expression (57).  
ICI 182,780 behaves as a GPER-1 agonist, stimulating GPER-1 activity which could 
contribute to the increase in IGF-1 mRNA levels.  These data establish that ER-α and 
ER-β are not involved in E2 stimulated IGF-1 mRNA expression in cultured BSC.  
Additionally, because ICI 182,780 is a GPER-1 agonist, the ability of this ER-α and ER-β 
antagonist to stimulate IGF-1 mRNA expression in cultured BSC suggests that E2 
activation of GPER-1 might play a role in E2 stimulated IGF-1 mRNA expression in 
these cells.  To further determine GPER-1 potential role a GPER-1 specific agonist, G1, 
was utilized to determine the GPER-1 role independent of the classical ER.  BSCs treated 
with G1 exhibited a 100% increase in IGF-1 mRNA levels (57) implying that GPER-1 is 
most likely involved in stimulating IGF-1 mRNA expression.  Additionally, it has been 
determined that muscle cells contain both mRNA and protein for GPER-1 (40; 58; 59).  
These data suggest that GPER-1 is involved in the IGF-1 mRNA increase and may be 
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mediating the E2 stimulated increase of IGF-1 expression which contributes to E2 
stimulated muscle growth.     
Estrogen effect on proliferation 
In 1% SSS and 2% SSS, conditions under which E2 did not stimulate IGF-1 or IGFR-1 
mRNA levels, E2 was still able to stimulate proliferation in BSCs (47; 51; 57).  This 
suggests that an increase in proliferation isn’t a result of increased IGF-1 or IGFR-1 
expression.  Treatment of cultured BSCs with ICI 182,780 (ER antagonist) resulted in 
suppressed E2 stimulated proliferation (47).  Additionally, in BSC cultures in which ER-
α was silenced E2 stimulation of proliferation was completely suppressed (51), indicating 
that ER-α is required for E2 stimulated BSC proliferation.     
Treatment of bovine satellite cells with AG1024 (IGFR-1 tyrosine kinase inhibitor) 
resulted in the suppression of E2 and LR3-IGF-1 (IGF-1 analog) stimulated proliferation 
(51).  Additionally, IGF-1 and E2 stimulated proliferation was suppressed in IGFR-1 
silenced bovine satellite cells (51).  This further supports that the function of IGFR-1 is 
necessary for E2 stimulated proliferation of bovine satellite cells.  The role of GPER-1 in 
E2 stimulated BSC proliferation was assessed by treating BSC with G1.  Treatment with 
G1 did not stimulate BSC proliferation indicating that activation of GPER-1 alone was 
not sufficient to stimulate BSC proliferation (57; 60). 
Estrogen effects on protein synthesis and protein degradation in BSC cultures 
In addition to an increase in proliferative activity, E2 also affected protein synthesis and 
protein degradation in BSCs under culture conditions in which neither IGF-1 nor IGFR-1 
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expression was increased.  Fused bovine satellite cell cultures treated with E2 exhibited a 
concentration dependent increase in protein synthesis, with 10nM E2 resulting in a 1.7 
fold increase in protein synthesis over control BSCs (60).  Fused BSCs treated with E2 
also exhibited a 70% decrease in protein degradation (60).   
ICI 182,780 suppressed the E2 stimulated increase in protein synthesis and E2 stimulated 
decrease in protein degradation in bovine satellite cells.  This indicates that ER-α is 
necessary for E2 to affect protein synthesis and degradation in bovine satellite cells 
grown in culture (60). Treatment of bovine satellite cell cultures with G1 had no effect on 
protein synthesis or protein degradation rates, indicating that E2 binding to GPER-1 was 
not sufficient to increase protein synthesis or decrease protein degradation in BSCs (60). 
Proposed mechanism of Estrogen action 
Although increased IGF-1 expression very likely plays a role in E2 stimulated BSC 
proliferation, based upon the compilation of literature detailing the estrogen mechanism 
of action in both non-muscle and muscle systems described in this review, we 
hypothesize that activation of both ER-α and GPER-1 initiate other pathways by which 
E2 can stimulate BSC proliferation. In addition to binding and activating ER-α, estrogen 
also can bind to and activate GPER-1.  When GPER-1 is activated the Gβγ protein 
complex is released and these subunits of the GPER-1 stimulate the activation of matrix 
metalloproteinase (MMPs).  MMPs enable the release of heparin-binding Epidermal 
Growth Factor (hb-EGF) from the cell surface.  The hb-EGF then is able to bind to 
epidermal growth factor receptor (EGFR) resulting in EGFR transactivation which 
mediates downstream pathways (28; 33; 34; 40; 42; 43).  Although the role of ER-α in 
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E2-stimulated BSC proliferation is not known (and will not be addressed in this thesis), 
E2-ER-α can reportedly form a complex with specific intracellular signaling molecules 
and this complex can interact with the intracellular subunit of IGFR-1 (26; 61) resulting 
in activation of the receptor which may interact with GPER-1 to stimulate BSC 
proliferation.  
This thesis will delve into the transactivation of EGFR and EGFR’s role in estrogen’s 
mechanism of action in bovine skeletal muscle.  In bovine satellite cells (BSCs) EGFR 
will be silenced utilizing siRNA and the impact of eliminating this receptor on E2, IGF-1, 
and hb-EGF stimulated proliferation in BSC cultures will be determined .  Additionally, 
EGFR, ER-α, and IGFR-1 mRNA and protein levels will be examined in control and 
EGFR silenced BSC cultures.  To further investigate the complex mechanism of estrogen 
stimulated proliferation in BSC cultures, the role of GPER-1 and MMPs will also be 
studied.  The effect of inhibiting MMP 2/9 on E2 and IGF-1 stimulated BSC proliferation 
will be determined.  Finally, GPER-1 will be inhibited and its impact upon E2 and IGF-1 
stimulated BSC proliferation will be ascertained.  This proposed plan of action will assist 
in elucidating estrogen’s mechanism of action in bovine skeletal muscle. 
 
 
 
22 
 
MANUSCRIPT 
Introduction 
The utilization of anabolic steroids is a very common management practice in the beef 
industry today.  According to the National Animal Health Monitoring System (NAHMS) 
(2000), 97% of feedlot cattle receive at least one steroid implant during their lifespan.  
The utilization of implants results in a significant reduction in production costs, showing 
an increase in value of $93 per animal (1).  The effects of implants are far reaching, as in 
addition to increasing production efficiency and being economically beneficial, they 
contribute to achieving the sustainability goals of the agricultural industry (3; 4; 62).  
However, there are concerns about steroid hormone residue building in the environment 
and possible negative health concerns about eating meat from anabolic steroid implanted 
animals.  Therefore, it is important to elucidate the mechanism of action of anabolic 
steroids on muscle growth in order to enhance understanding and to potentially devise 
new methodologies that may achieve similar positive growth enhancing effects without 
the negative concerns of steroid hormone use.   
A trenbolone acetate (TBA) and estrogen (E2) combination implant given to steers 
increases average daily gain (ADG) 18-36% and feed efficiency 8-34% over non-
implanted steers (1; 6-9).  In order to achieve this increase in production characteristics, 
postnatal muscle growth must be increased.  Satellite cells are the source of  nuclei 
needed to support postnatal muscle growth (12).  Estrogen is able to stimulated bovine 
satellite cell (BSC) proliferation (63).  In proliferating cells where ER-α was silenced 
LR3-IGF-1(IGF-1 analog) and heparin-binding Epidermal Growth Factor (hb-EGF) were 
able to increase proliferation whereas the E2 stimulation of proliferation was completely 
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suppressed (51), indicating that ER-α is required for E2 stimulated BSC proliferation.  
However, it has been shown that rapid estrogen action is not completely dependent on 
ER-α  and ER-β.  The G protein-coupled estrogen receptor (GPER)-1 also mediates 
estrogen function (26).  The role of GPER-1 in E2 stimulated BSC proliferation was 
assessed by treating BSCs with G1.  Treatment with G1 did not stimulate BSC 
proliferation indicating that activation of GPER-1 alone was not sufficient to stimulate 
BSC proliferation (57; 60). 
However, based upon the compilation of literature detailing the estrogen mechanism of 
action in non-muscle and muscle systems, we hypothesize that activation of both ER-α 
and GPER-1 is necessary in order for E2 to stimulate BSC proliferation. In addition to 
binding and activating ER-α, estrogen also can bind to and activate GPER-1.  In cancer 
cells when GPER-1 is activated the Gβγ protein complex is released and these subunits of 
the GPER-1 stimulate the activation of matrix metalloproteinase (MMPs).  The MMPs 
enable the release of heparin-binding Epidermal Growth Factor (hb-EGF) from the cell 
surface.  The hb-EGF then is able to bind to epidermal growth factor receptor (EGFR) 
resulting in EGFR transactivation which mediates downstream pathways that regulate 
cell proliferation (28; 33; 34; 40; 42; 43). The objective of this study is to determine if 
EGFR is required for E2 stimulated proliferation in BSCs and further contribute to 
elucidating estrogen’s mechanism of action in bovine skeletal muscle.  
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Materials and Methods 
Bovine Satellite Cell Isolation 
Satellite cells were isolated from yearling crossbred steers that had never received an 
anabolic steroid implant and had been on full feed for a 3 week period.  Steers were 
euthanized using procedures approved by the University of Minnesota Institutional 
Animal Care and Use Committee.  Using sterile technique, approximately 1 kilogram of 
semimembranosus muscle was dissected and transported to the cell culture laboratory.  
Connective tissue was removed from the muscle and the muscle was passed through a 
sterile meat grinder.  The ground muscle was incubated with 0.1% pronase in Earl’s 
balanced salt solution for 1 hour at 37˚C with mixing at every 10 minute interval.  From 
the time the animal was harvested until muscle is mixed with pronase only 30 minutes are 
allowed to pass.  Following the incubation period the mixture was centrifuged at 1,500 x 
g for 4 minutes, the pellet was re-suspended in PBS (140mM NaCl, 1 mM KH2PO4, 3mM 
KCl, 8 mM Na2HPO4, pH 7.4), and the suspension was centrifuged at 500 x g for 10 
minutes.  The resultant supernatant was centrifuged at 1,500 x g for 10 minutes to pellet 
the mononucleated cells.  The PBS wash and differential centrifugation was repeated two 
more times.  The resulting mononucleated cell preparation was suspended in 4˚C 
Dulbecco Modified Eagle Media (DMEM) containing 10% Fetal Bovine Serum (FBS) 
and 10% (vol/vol) dimethylsulfoxide (DMSO) and frozen at -80˚C.  Cells were stored 
frozen in liquid nitrogen for future use.   
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3
H-thymidine incorporation assays 
BSCs were grown on 2cm
2
 well plates.  Prior to plating of cells the wells were coated 
with 250µl BD Matrigel Matrix (0.95mg/mL) + DMEM.  Cells were plated in DMEM 
containing 10% fetal bovine serum (FBS) at a plating density (cells isolated from 0.16g 
muscle tissue/cm
2
) empirically established so that cultures were approximately 50% 
confluent when proliferation rate was determined.  At 72 hours media was removed, cells 
were washed once with warm DMEM and test media (0.5mL) containing DMEM plus 
1% insulin-like growth factor binding protein (IGFBP)-3-free swine serum (prepared by 
passing sera obtained from 6 week old male pigs castrated within 1 week of birth through 
an IGFBP-3 immunoaffinity column) (51) containing 10nM E2 (Steraloids Inc, Newport, 
RI; catalog no. E0950-000) or other growth factors to be tested was applied.  At 93 hours 
3
H-thymidine was added to the media on the cells at a concentration of 1mCi/mL and 
incubated for 3 hours.  Following the incubation media was removed and cells were 
washed 3 times with cold DMEM.  Cells were fixed with 1mL of cold 5% trichloroacetic 
acid (TCA) overnight at 4˚C.  Unincorporated 3H-thymidine was removed when 5% TCA 
was removed and cells were washed twice with cold 5% TCA.  Incorporation of 
3
H-
thymidine into cellular DNA was determined by dissolving the cell material in 0.5M 
sodium hydroxide (NaOH) for 30 minutes.  Cell material was then placed in scintillation 
vials and counted in a scintillation counter.  All experiments contained triplicate 
measurements.   
To assess the effects of GPER-1 inhibitors on proliferation of cultured BSC, bovine 
satellite cells were plated in DMEM/10%FBS as described above.  At 72 hours media 
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was removed, cells were washed once with warm DMEM and incubated with 0.5mL 
DMEM/1% IGFBP-3-free swine serum or DMEM/1% IGFBP-3-free swine serum plus 
20nM of the specific GPER-1 inhibitors G15 (Azano Pharmaceuticals, Inc. Albuquerque, 
NM) or G36 (Azano Pharmaceuticals, Inc. Albuquerque, NM) for 30 minutes.   
Following the 30 minute incubation period media was removed and BSC cultures were 
treated with 0.5mL DMEM/1% IGFBP-3-free swine serum or DMEM/1% IGFBP-3-free 
swine serum containing 25ng LR3-IGF-1/ml or 10nM E2 +/- 20nM G15 or G36.  At 93 
hours 
3
H-thymidine was added to the media on the cells and the rest of the protocol was 
conducted as stated previously.   
 For MMP2/9 inhibitor assays, Bovine satellite cell preparations were thawed and plated 
in DMEM/10% FBS as described above.  At 72 hours media was removed, cells were 
washed once with warm DMEM and cultures were incubated with 0.5mL DMEM/1% 
IGFBP-3-free swine serum or DMEM/1% IGFBP-3-free swine serum plus 10µM 
MMP2/9 inhibitor (MMP-2/MMP-9 Inhibitor II, Calbiochem, Billerica, MA, Catalog no. 
444249) for 30 minutes.   Following the 30 minute incubation period media was removed 
and cultures were treated with 0.5mL DMEM/1% IGFBP-3-free swine serum or 
DMEM/1% IGFBP-3-free swine serum containing 25ng LR3-IGF-1/ml or 10nM E2 +/- 
10µM MMP2/9 inhibitor.  At 93 hours 
3
H-thymidine was added to the media on the cells 
and the rest of the protocol was conducted as stated previously.   
Small interfering RNA knockdown of EGFR 
Silencing of EGFR expression in BSC cultures was achieved utilizing custom-designed 
small interfering RNA (siRNA) specific for bovine EGFR (Qiagen, Valencia, CA 5’-
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CUA CGG ACU CCA ACU UCU ATT-3’ (sense strand)) and Lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA).  In every experiment controls included cells 
treated with a non-specific siRNA with no homology to any known mammalian gene 
(Allstars siRNA; Qiagen Ca#1027280).  Bovine satellite cell preparations were thawed 
and plated on culture dishes precoated with reduced growth factor basement membrane 
Matrigel (Becton Dickson, Franklin Lakes, NJ) at 0.19mg/mL diluted in DMEM.  
Satellite cells obtained from 0.1g muscle tissue/cm
2
 were plated per cm
2
.  Cells were 
plated in 10% Fetal Bovine Serum in DMEM and incubated at 37˚C, 5% CO2 in a water 
saturated environment.  At 72 hours cells were washed once with warm DMEM and 
DMEM + 10% FBS without any antibiotics was put on the cells.  Transfection complex 
was formed by diluting Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) and EGFR 
siRNA or Allstars siRNA in Opti-MEM I Reduced Serum Media (Invitrogen, Carlsbad, 
CA) and incubating for 10 minutes at room temperature.  Following this incubation, the 
transfection complex was added to the media on the cells (200µl/mL of culture media) to 
yield a final level of 1.5µl Lipofectamine/mL media and 2 nM EGFR or Allstars siRNA 
in the culture media.  This transfection media was incubated on the cells for 6 hours, and 
then removed and replaced with fresh DMEM/10% FBS with antibiotics for 18 hours.  At 
96 hours cells designated for proliferation received 0.5mL test media consisting of 
DMEM/ 1% IGFBP-3 free swine serum (SSS), 10nM E2 (Steraloids Inc, Newport, RI; 
catalog no. E0950-000), 25ng LR3-IGF-1/mL (GroPep BioReagents Pty Ltd, Thebarton, 
SA Australia; Catalog no.Bu100; an IGF-1 analogue that binds normally to IGFR-1 but 
has little or no affinity for IGF binding proteins) (51), 5ng hb-EGF/mL (R&D Systems, 
Minneapolis, MN; Catalog no. 259-HE), or 10% FBS, and at 120 h proliferation rate was 
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determined using the  
3
H-thymidine incorporation protocol.  At 96 hours cells designated 
for isolation of RNA or protein received 1mL 1% SSS and at 120 h RNA and protein 
were isolated as described below.   
Quantitative RT-PCR sample preparation and RNA isolation 
RNA was isolated from bovine satellite cells with the use of Absolutely RNA Microprep 
Kit (Agilent, Santa Clara, CA).  After a phenol chloroform extraction of the cell lysate, 
RNA was isolated according to the manufacturer’s recommended protocol.  Samples 
were treated with DNase while bound to the fiber matrix during the isolation process.  
RNA was then reverse-transcribed to produce first-strand complementary DNA (cDNA). 
Quantitative RT-PCR 
Quantitative RT-PCR was utilized to measure the quantity of EGFR, IGFR-1β, and ER-α 
mRNA relative to the quantity of cyclophilin mRNA in total mRNA.  Complementary 
DNA was generated from 1.0µg RNA utilizing Taq-Man Reverse Transcriptase Reagents 
(Applied Biosystems, Carlsbad, CA) and the manufacturer’s recommended protocol.  
Random hexamers were used as the primers in cDNA synthesis.  The relative quantity of 
the desired cDNA was measured utilizing SYBR Green PCR Master Mix (Applied 
Biosystems), forward and reverse bovine primers (described in Table 1), and 1µL of 
cDNA mixture.  Assays were performed in the GeneAmp 7,300 Sequence Detection 
System (Applied Biosystems, Grand Island, NY) with the use of thermal cycling 
parameters recommended by the manufacturer (40 cycles of 15 seconds at 95˚C and 1 
minute at 60˚C).   
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Western immunoblots 
Cultured cells were lysed in tracking dye (20% SDS, 1M Tris-HCl pH 6.8, Glycerol, 
0.4% Bromophenol blue, Water, β-Mercaptoethanol) or lysis buffer (50mM Tris-HCl 
pH8, 150mM NaCl, 1% Igepal, 1mM EDTA, 1mM NaF).  The samples in tracking dye 
were boiled and centrifuged to remove insoluble fragments.  The samples in lysis buffer 
were used solely for a BCA protein assay to determine protein concentration.  Utilizing 
the protein concentration an approximation of equal amounts of protein from each sample 
in tracking dye were electrophoresed on a 7.5% SDS polyacrylamide gel, and then 
electrophoretically transferred to a nitrocellulose membrane.  Once the protein was 
transferred to the nitrocellulose membrane the membrane was washed twice with TBS 
and blocked for 1 hour with 5% NFDM+TBST.  Specific details for individual proteins’ 
primary anti-bodies, dilution reagent, and anti-body incubation period are provided in 
Table 2.  Following the primary antibody incubation period, the membranes were 
extensively washed, and incubated with a secondary antibody for 1 hour.  Specific details 
for individual proteins’ secondary anti-bodies and dilution reagent are provided in Table 
2.  Following the secondary anti-body incubation period the membrane was washed 
extensively and incubated for 5 minutes in WesternSure Premium Chemiluminescent 
substrate (LI-COR, Lincoln, NE) and visualized with C-Digit Blot Scanner (LI-COR, 
Lincoln, NE).  Blots were stripped with Restore Western blot Stripping Buffer (Thermo 
Scientific, Rockford, IL) and probed with anti-tubulin as a loading control.  
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Statistical Analysis 
All data was analyzed using the MIXED procedure of SAS (SAS 9.3, Cary, NC).  In each 
experiment, data from at least three separate assays each with triplicate counts were 
combined and analyzed.  Significant interactions were determined at p<0.05 and least 
squares means were separated using Tukey’s (p<0.05) 
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Results 
Effects of silencing EGFR expression on ER-α and IGFR-1β mRNA expression 
Treatment of BSC cultures with EGFR siRNA resulted in significant knocked down of 
EGFR mRNA expression compared to BSC cultures treated with non-specific siRNA 
(p<0.05) (Figure 1).  Additionally, because ER-α and IGFR-1β have been shown to play 
a role in E2 stimulated satellite cell proliferation, we also looked at the effect of EGFR 
siRNA treatment on expression of  ER-α and IGFR-1β mRNA.  Treatment of BSCs with 
EGFR siRNA had no impact upon ER-α (Figure 2) or IGFR-1β mRNA (Figure 3) 
expression indicating that the EGFR siRNA knockdown is specific for EGFR.   
Effects of silencing EGFR on EGFR, ER-α and IGFR-1β protein levels 
To further establish the efficacy of EGFR knockdown, the EGFR protein levels in BSCs 
treated with EGFR siRNA and non-specific siRNA were examined.  In western 
immunoblots of protein lysates from BSC cultures treated with EGFR siRNA, EGFR 
protein was undetectable in comparison to the protein level in BSCs treated with non-
specific siRNA (Figure 4).  Table 3 shows that the ratio of EGFR protein to tubulin was 4 
for non-specific siRNA treated cells and 0 for EGFR siRNA treated cells.  Treatment of 
BSCs with EGFR siRNA had little if any impact upon ER-α protein levels (Figure 5).  
The ratio of ER-α protein to tubulin was 1.64 for non-specific siRNA and 1.35 for EGFR 
siRNA treated cells (Table 3).  Bovine satellite cell cultures treated with EGFR siRNA 
had reduced levels of IGFR-1β protein in comparison to non-specific treated BSCs 
(Figure 6).  The ratio of IGFR-1β protein to tubulin was 7.57 for non-specific siRNA and 
32 
 
2.25 for EGFR siRNA treated cells (Table 3).  This implies that functional EGFR is 
necessary to maintain IGFR-1β protein levels in BSC.     
Effect of silencing EGFR expression on E2 stimulated proliferation in cultured BSCs 
To determine the impact of EGFR in E2 stimulated proliferation of bovine satellite cells 
we have evaluated the effect of silencing EGFR on the ability of  E2, LR3-IGF-1, hb-
EGF, and 10% FBS to stimulated proliferation.  Figure 7 shows that silencing EGFR 
expression in BSC cultures completely suppressed hb-EGF, IGF-1, and E2 stimulated 
BSC proliferation (p<0.05).  EGFR silenced cells respond to FBS indicating they are able 
to respond to mitogenic stimulation; however their response is less than cells treated with 
non-specific siRNA (Figure 7). This lesser response may reflect the inability of EGFR 
silenced cells to respond to EGF, E2, and possibly IGF-1.  
Effects of an inhibitor of GPER-1 on E2 stimulated proliferation in cultured BSCs 
In a multitude of tissues it has been shown that the G protein-coupled estrogen receptor 
(GPER)-1 contributes to rapid non-genomic estrogen response.  These studies have 
shown that binding of E2 to GPER-1 results in transactivation of the EGFR.  To assess 
the role of GPER-1 in E2 stimulated proliferation of BSCs, we evaluated the effect of 
G15 and G36 (specific GPER-1 antagonists) on E2 and LR3-IGF-1 (IGF-1 analog) 
stimulated proliferation.  Figure 8 portrays that both G15 and G36 completely suppressed 
E2 stimulated proliferation of BSCs (p<0.05), indicating that GPER-1 is necessary for E2 
stimulated proliferation.  However, G15 and G36 had no impact upon LR3-IGF-1 
stimulated proliferation (Figure 8).  Thus, it appears that GPER-1 is not required for IGF-
1-stimulated BSC proliferation.     
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Effects of an inhibitor of MMP2/9 on E2- and IGF-1-stimulated proliferation in cultured 
BSCs 
Estrogen mediated activation of GPER-1 stimulates the activity of matrix 
metalloproteinases (MMP) 2/9 which contributes to the transactivation of EGFR in a 
variety of non-muscle tissues.  To examine the potential role of MMP2 and MMP9 in E2 
stimulated proliferation of bovine satellite cells, we assessed the effect of a MMP2/9 
inhibitor on E2 stimulated proliferation.  The MMP2/9 inhibitor completely suppressed 
E2 stimulated BSC proliferation (p<0.05), indicating that MMP2/9 activity is necessary 
for E2 stimulated proliferation.   We also examined the effect of the MMP2/9 inhibitor on 
LR3-IGF-1 stimulated BSC proliferation. The MMP2/9 inhibitor partially suppressed 
IGF-1 stimulated proliferation (p<0.05) (Figure 9).  The proliferation rate was 
significantly lower than the IGF-1 proliferation rate; however, it was not suppressed to 
the level of the control BSCs.   
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Discussion 
Estrogen is an anabolic steroid that is commonly used as a beef management tool.  
Anabolic steroid implantation in steers has been linked to an increase in average daily 
gain (ADG) of 18-36% and feed efficiency of 8-34% over non-implanted steers (1; 6-9), 
both of which are important production characteristics contributing to muscle growth.  
Treatment of steers with estrogenic implants resulted in an increase in protein accretion 
and increased body weight gain (64).  Determining the mechanism of action that estrogen 
utilizes to increase and support postnatal muscle growth is important to further improve 
beef production practices.  Satellite cells play a crucial role in postnatal muscle growth by 
providing the additional nuclei necessary to support muscle growth.  Skeletal muscle 
hypertrophy requires both myofiber size increase and nuclei quantity increase to support 
additional myofiber growth, both of which estrogen plays a role in.  Estrogen has been 
shown to increase proliferative activity in a multitude of cells including bovine satellite 
cells (24; 25).   
Our present study utilized the knockdown of EGFR to further elucidate the interaction of 
EGFR in the E2 mechanism of action within bovine satellite cells.  Treatment of BSC 
cultures with EGFR siRNA resulted in significant knocked down of EGFR mRNA 
expression compared to BSC cultures treated with non-specific siRNA (Figure 1).  To 
further establish the efficacy of EGFR knockdown, western immunoblots of protein 
lysates from BSC cultures treated with EGFR siRNA were examined.  EGFR protein was 
eliminated in comparison to the protein level in BSCs treated with non-specific siRNA 
(Figure 4).  Additionally, Table 3 shows that the ratio of EGFR protein to tubulin was 4 
for non-specific siRNA treated cells and 0 for EGFR siRNA treated cells.  Our present 
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study indicates that when EGFR is silenced hb-EGF stimulated proliferation is 
suppressed in bovine satellite cells, as expected.  Additionally, neither E2 nor IGF-1 are 
able to stimulate proliferation in EGFR silenced BSCs.  EGFR silenced cells respond to 
10% FBS indicating they are able to respond to mitogenic stimulation; however their 
response is less than cells treated with non-specific siRNA.  This lesser response is not 
surprising due to the fact that the cells are non-responsive to E2, IGF-1, and hb-EGF.  
The essential role of EGFR in E2 and IGF-1 stimulated proliferation is supported by 
studies in non-muscle cells where EGFR was rendered nonfunctional either by using 
AG1478 (EGFR tyrosine kinase inhibitor) or by knocking down EGFR with a siRNA.  
These studies show that EGFR inhibition results in inhibition of proliferation induced by 
E2, IGF-1, and EGF (34; 36-38) in MCF-7 and COS-7 cancer cells.  Additionally, 
AG1478 has been shown to suppress E2 and hb-EGF stimulated proliferation in bovine 
satellite cells (26).  This accumulation of data supports our current findings that 
suppression of EGFR also suppresses activity of ER-α and IGFR-1.   This supports the 
model that EGFR is the downstream converging point for ER-α and IGFR-1 action.   
Due to the fact that E2 and IGF-1 stimulated proliferation is suppressed in EGFR silenced 
bovine satellite cells, we also looked at the effect of EGFR siRNA treatment on 
expression of ER-α and IGFR-1 mRNA.  Treatment of BSCs with EGFR siRNA had no 
impact upon ER-α (Figure 2) or IGFR mRNA (Figure 3) expression indicating that the 
EGFR siRNA knockdown is specific for EGFR.  Treatment of BSCs with EGFR siRNA 
had little if any impact upon ER-α protein levels (Figure 5).  The ratio of ER-α protein to 
tubulin was 1.64 for non-specific siRNA and 1.35 for EGFR siRNA treated cells (Table 
3).  Bovine satellite cell cultures treated with EGFR siRNA had reduced levels of IGFR-
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1β protein in comparison to non-specific siRNA treated BSCs (Figure 6).  The ratio of 
IGFR-1β protein to tubulin was 7.57 for non-specific siRNA and 2.25 for EGFR siRNA 
treated cells (Table 3).  Since IGFR-1β mRNA expression is not reduced in EGFR 
silenced cells, reduction of IGFR-1β is not the result of non-specific effects of the EGFR 
siRNA.  Instead, it appears that silencing of EGFR results in a post-transcriptional 
reduction in IGFR-1β protein levels.  This is supported by a study done in breast cancer 
cells where EGFR was knocked down, resulting in an decrease in IGFR-1β protein levels 
while the IGFR-1β mRNA levels were not impacted (65).  Since previous studies have 
shown that E2 stimulated satellite cell proliferation is suppressed in BSC in which IGFR-
1β is silenced (51), the reduction in IGFR-1β protein level in EGFR-silenced cells 
complicates interpretation of the role of EGFR in E2 stimulated BSC proliferation.  
Although it is clear that functional EGFR is necessary for E2 stimulated proliferation of 
BSC, it is not clear to what extent.  The study done in breast cancer indicated that EGFR 
protects IGFR-1β from degradation and impacts IGFR-1β protein stability (65).  EGFR 
may function to maintain the level of IGFR-1β which is necessary for E2 stimulated 
proliferation or the transactivation of EGFR may directly stimulate proliferation.  
Additionally, it is possible that the role of EGFR in E2 stimulated BSC proliferation may 
involve both of these mechanisms.  Further research is required to elucidate the roles of 
EGFR and IGFR-1 in E2-stimulated BSC proliferation.  
Numerous studies in non-muscle cells have shown that E2 may stimulate proliferation by 
binding to GPER-1 which results in transactivation of EGFR (28; 33; 34; 40; 42; 43).  
Consequently, to further clarify the role of EGFR transactivation in E2 stimulated BSC 
proliferation; we have examined the effect of inhibiting GPER-1 on E2-stimulated BSC 
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proliferation.  Our study indicates that when GPER-1 is suppressed E2 stimulated 
proliferation is inhibited indicating that E2 binding to GPER-1 is involved in E2 
stimulated bovine satellite cell proliferation.  This was also seen in uterine epithelial cells 
were G15 reduced E2 stimulated proliferation by 50% (26).  However, treatment with G1 
(GPER-1 agonist) did not stimulate BSC proliferation indicating that activation of GPER-
1 alone was not sufficient to stimulate BSC proliferation (57; 60).  Additionally, 
treatment of cultured BSCs with ICI 182,780 (ER antagonist) resulted in suppressed E2 
stimulated proliferation (47) indicating that ER-α or ER-β activity was required for E2 
stimulated BSC proliferation  In BSC cultures in which ER-α was silenced E2 stimulation 
of proliferation was completely suppressed (51), indicating that ER-α and not ER-β is 
required for E2 stimulated BSC proliferation.  These results establish that E2 functions by 
activating both GPER-1 and ER to stimulate BSC proliferation.  Additionally, our results 
show that GPER-1 is not involved in IGF-1 stimulated BSC proliferation because 
inhibition of GPER-1 has no impact on IGF-1 stimulated BSC proliferation.  
Various studies in non-muscle tissue indicate that MMP2/9 play an important role in 
GPER-1 mediated proliferation.  Ligand binding to GPER-1 results in activation of 
MMP2/9 and subsequent proteolytic release of membrane bound hb-EGF which binds to 
EGFR resulting in transactivation of the EGFR.  In breast cancer cells when the MMPs 
are inhibited they are unable to cleave the hb-EGF, reducing the available free hb-EGF.  
This indicates that MMPs are necessary for E2/GPER-1 mediated release of hb-EGF, a 
crucial aspect of EGFR transactivation (42; 49; 50).  The reduction in hb-EGF resulted in 
the EGFR phosphorylation being suppressed (42; 49; 50).  Similarly, our study showed 
that when MMP2/9 activity is inhibited in BSC cultures, E2 stimulated proliferation is 
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also suppressed.  This finding supports the hypothesis that GPER-1 stimulated 
transactivation of EGFR is involved in E2 stimulated proliferation of BSC.   
Our studies also show that IGF-1 stimulated proliferation of cultured BSC is suppressed 
when MMP2/9 are inhibited.  These data suggest that there is an interaction between 
IGFR-1 and MMP2/9 but further studies are needed to clarify this relationship.   
The compilation of results from this study contributes to the theory that binding of E2 to 
GPER-1 results in transactivation of the Epidermal Growth Factor Receptor (EGFR) 
(Figure 10) (28; 33; 34; 40; 42; 43).  Estrogen binds to GPER-1 with high affinity and 
that binding activates GPER-1 releasing the Gβγ protein complex (44).  These subunits of 
the GPER-1 stimulate the activity of matrix metalloproteinases (MMP) 2/9.  MMPs 
enable the proteolytic cleavage and release of heparin-binding Epidermal Growth Factor 
(hb-EGF) from the cell surface.  The cleaved hb-EGF is able to bind to Epidermal 
Growth Factor Receptor (EGFR) resulting in EGFR transactivation which mediates 
downstream pathways (28; 33; 34; 40; 42; 43) which regulates proliferation.  GPER-1 
transactivation of EGFR is crucial for the rapid, non-genomic response to E2 in cells.  
Additionally, it appears that IGFR-1 also is involved in E2 stimulated BSC proliferation 
and that functional EGFR is required in order to maintain IGFR-1 level. Further studies 
are required to elucidate the relationship and specific roles of IGFR-1 and EGFR in the 
mechanism of E2 stimulated BSC proliferation. 
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Table 1. Nucleotide sequences for bovine quantitative real-time PCR primers 
 Primer  GenBank accession 
no. 
IGFR-1β 
primers 
 NM_001244612 
Forward 5’-GCA GAT GGC ATG GCA TAC CT-3’  
Reverse 5’-TCT TCG GCC ACC ATG CA-3’  
ESR1 primers  NM_001001443 
Forward 5’-ACG ATT GAT AAA AAC AGG AGG 
AAG A-3’ 
 
Reverse 5’-GCC TTT CAT CAT GCC CAC TT-3’  
EGFR primers  XM_002696890.2 
Forward 5’- CCC CAG GCC ATG AAC GT -3’  
Reverse 5’- GCA GTG AGG GCC ATC AAT GT -3’  
Cyclophilin  NM_178320 
Forward 5’-GGT CCT GGC ATC TTG TCC AT-3’  
Reverse 5’-TGG CAG TGC AAA TGA AAA ACT 
G-3’ 
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Table 2. Antibodies for western immunoblots and their designated protein, source, 
catalog number, dilution rate, dilution reagent, and incubation period.  
Designated 
Protein 
Specific 
Antibody 
Antibody 
Source 
Catalog 
Number 
Antibody 
Dilution 
Rate 
Antibody 
Dilution 
Reagent 
Antibody 
Incubation 
Period 
EGFR 
Primary 
anti-EGF-
Rec  
Cell Signaling 2646 1:1000 5% BSA 
+TBST 
Overnight 
IGFR-1β 
Primary 
anti-IGF-1 
Rec β 
Cell signaling 3027 1:3000 5% BSA 
+TBST 
Overnight 
ER-α 
Primary 
anti-ESR1 Santa Cruz 
Biotechnology 
Inc 
sc-
71064 
1:200 5% 
NFDM 
+TBST 
1 hour 
Tubulin 
Primary 
anti-β 
Tubulin 
Santa Cruz 
Biotechnology 
Inc 
sc-
51712 
1:1000 5% 
NFDM 
+TBST 
1 hour 
EGFR 
Secondary 
HRP-
conjugated 
goat anti-
rabbit IgG 
Cell Signaling  7074 1:2000 5% 
NFDM 
+TBST 
1 hour 
IGFR-1β 
Secondary 
HRP-
conjugated 
goat anti-
rabbit IgG 
Cell Signaling  7074 1:2000 5% 
NFDM 
+TBST 
1 hour 
ER-α 
Secondary 
goat anti-
mouse 
IgG-HRP 
Santa Cruz  sc-2005 1:2000 5% 
NFDM 
+TBST 
1 hour 
Tubulin 
Secondary 
HRP-
conjugated 
goat anti-
mouse 
IgM 
Santa Cruz Sc-2064 1:10,000 5% 
NFDM 
+TBST 
1 hour 
 
 
 
 
 
 
41 
 
Table 3. Ratio of EGFR, IGFR-1 and ER-α protein levels to tubulin levels in Western 
immunoblots of protein lysates obtained from BSC cultures treated with EGFR siRNA or 
Non-specific siRNA. 
Protein Non-specific siRNA EGFR siRNA 
EGFR 4 0 
IGFR-1β 7.57 2.25 
ER-α 1.64 1.35 
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Figure 1. Relative EGFR mRNA level in bovine satellite cell (BSC) cultures treated with 
non-specific siRNA and in BSC cultures treated with EGFR siRNA.  Cells were plated as 
detailed in Materials and Methods, and during the first 72 hours were grown in Dulbecco 
Modified Eagle Medium (DMEM) containing 10% FBS.  At 72 hours cells were fed with 
1mL 10%FBS+DMEM without any antibiotics and the transfection complex containing 
200 µl Opti-MEM I Reduced Serum Media, 1.5 µl Lipofectamine RNAiMAX, and either 
control(non-specific) or EGFR siRNA (2nM).  This antibiotic-free media was incubated 
on the cells for 6 hours. After 6 hours media was removed and fresh 10%FBS+DMEM 
with antibiotics was added and cells were incubated for an additional 18 hours.  At 96 
hours total RNA was isolated and quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) assays were utilized to determine EGFR mRNA levels relative to the 
level of cyclophilin mRNA in cultures treated with non-specific siRNA or EGFR siRNA. 
Relative EGFR mRNA levels are significantly reduced (p < 0.05) in EGFR siRNA-
treated cultures. Data are the pooled mean ± SEM from 8 separate assays each containing 
triplicate determinations and using cells isolated from two different animals.  Bars with 
different letters are significantly different (p<0.05).  
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Figure 2. Relative IGFR-1β mRNA level in bovine satellite cell (BSC) cultures treated 
with non-specific siRNA and in BSC cultures treated with EGFR siRNA.  Cells were 
plated as detailed in Materials and Methods, and during the first 72 hours were grown in 
Dulbecco Modified Eagle Medium (DMEM) containing 10% FBS.  At 72 hours cells 
were fed with 1mL 10%FBS+DMEM without any antibiotics and the transfection 
complex containing 200 µl Opti-MEM I Reduced Serum Media, 1.5 µl Lipofectamine 
RNAiMAX, and either control(non-specific) or EGFR siRNA (2nM).  This antibiotic-
free media was incubated on the cells for 6 hours. After 6 hours media was removed and 
fresh 10%FBS+DMEM with antibiotics was added and cells were incubated for an 
additional 18 hours.  At 96 hours total RNA was isolated and quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR) assays were utilized to determine 
IGFR mRNA levels relative to the level of cyclophilin mRNA in cultures treated with 
non-specific siRNA or EGFR siRNA. Relative IGFR mRNA levels were not significantly 
reduced (p < 0.05) in EGFR siRNA-treated cultures. Data are the pooled mean ± SEM 
from 8 separate assays each containing triplicate determinations and using cells isolated 
from two different animals.  Bars with different letters are significantly different 
(p<0.05).   
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Figure 3. Relative ER-α mRNA level in bovine satellite cell (BSC) cultures treated with 
non-specific siRNA and in BSC cultures treated with EGFR siRNA.  Cells were plated as 
detailed in Materials and Methods, and during the first 72 hours were grown in Dulbecco 
Modified Eagle Medium (DMEM) containing 10% FBS.  At 72 hours cells were fed with 
1mL 10%FBS+DMEM without any antibiotics and the transfection complex containing 
200 µl Opti-MEM I Reduced Serum Media, 1.5 µl Lipofectamine RNAiMAX, and either 
control(non-specific) or EGFR siRNA (2nM).  This antibiotic-free media was incubated 
on the cells for 6 hours. After 6 hours media was removed and fresh 10%FBS+DMEM 
with antibiotics was added and cells were incubated for an additional 18 hours.  At 96 
hours total RNA was isolated and quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) assays were utilized to determine ER-α mRNA levels relative to the 
level of cyclophilin mRNA in cultures treated with non-specific siRNA or EGFR siRNA. 
Relative ER-α mRNA levels were not significantly reduced (p < 0.05) in EGFR siRNA-
treated cultures. Data are the pooled mean ± SEM from 8 separate assays each containing 
triplicate determinations and using cells isolated from two different animals.  Bars with 
different letters are significantly different (p<0.05).   
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Figure 4. Western immunoblot showing EGFR protein levels in bovine satellite cell 
(BSC) cultures treated with non-specific siRNA (Control siRNA) or EGFR siRNA 
(EGFR siRNA).  Cells were lysed in tracking dye (20% SDS, 1M Tris-HCl pH6.8, 
Glycerol, 0.4% Bromophenol blue, Water, β-Mercaptoethanol) and analyzed using 
Western immunoblotting.  Tubulin was used as a loading control.  Cells treated with 
EGFR siRNA show no detectable EGFR protein.  
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Figure 5. Western immunoblot showing ER-α protein levels in bovine satellite cell (BSC) 
cultures treated with non-specific siRNA (Control siRNA) and EGFR siRNA (EGFR 
siRNA).  Cells were lysed in tracking dye (20% SDS, 1M Tris-HCl pH6.8, Glycerol, 
0.4% Bromophenol blue, Water, β-Mercaptoethanol) and analyzed using Western 
immunoblotting.  Tubulin was used as a loading control.  Levels of ER-α protein in 
EGFR siRNA treated were not reduced compared to levels in non-specific siRNA treated 
BSCs.   
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Figure 6. Western immunoblot showing IGFR-1β protein levels in bovine satellite cell 
(BSC) cultures treated with non-specific siRNA (Control siRNA) and EGFR siRNA 
(EGFR siRNA).  Cells were lysed in tracking dye (20% SDS, 1M Tris-HCl pH6.8, 
Glycerol, 0.4% Bromophenol blue, Water, β-Mercaptoethanol) and analyzed using 
Western immunoblotting.  Tubulin was used as a loading control.  Levels of IGFR-1 
protein in EGFR siRNA treated BSC are reduced compared to the levels in BSC treated 
with non-specific siRNA.   
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Figure 7. 
3
H-Thymidine incorporation assay showing the effects of LR3-IGF-1 (IGF-1), 
estradiol (E2), heparin binding-epidermal growth factor (hb-EGF) or fetal bovine serum 
(FBS) on proliferation in bovine satellite cell (BSC) cultures treated with non-specific 
small interfering RNA (siRNA) or EGFR siRNA. Cells were plated as detailed in 
Materials and Methods, and during the first 72 hours were grown in Dulbecco Modified 
Eagle Medium (DMEM) containing 10% FBS.  At 72 hours cells were fed with 0.5mL 
10%FBS+DMEM without any antibiotics and the transfection complex containing 100 µl 
Opti-MEM I Reduced Serum Media, 0.75 µl Lipofectamine RNAiMAX, and either 
control(non-specific) or EGFR siRNA (2nM).  This antibiotic-free media was incubated 
on the cells for 6 hours. After 6 hours media was removed and fresh 10%FBS+DMEM 
with antibiotics was added to the cells and incubation was continued for 18 hours.  At 96 
hours cultures were treated with DMEM/1%IGFBP-3-free swine serum (Ctrl) or 
DMEM/1%IGFBP-3-free swine serum plus 25ng LR3-IGF-1/mL (IGF-1), 5ng 
hbEGF/mL (hb-EGF), 10nM E2 (E2) or 10% FBS (10% FBS). Bars with different 
letters are significantly different (p < 0.05).  Data are the pooled mean ± SEM from 8 
separate assays each containing triplicate determinations and using cells isolated from 
two different animals.    
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Figure 8. 
3
H-Thymidine incorporation assay showing the effects of LR3-IGF-1 (IGF-1) 
or  estradiol (E2) on proliferation in bovine satellite cell (BSC) cultures treated with G15 
and G36 (specific G protein-coupled estrogen receptor (GPER)-1 antagonists).  Cells 
were plated as detailed in Materials and Methods, and during the first 72 hours were 
grown in Dulbecco Modified Eagle Medium (DMEM) containing 10% FBS.  At 72 hours 
cells were treated with DMEM/1% IGFBP-3-free swine serum (Ctrl) or DMEM/1% 
IGFBP-3-free swine serum plus 25ng LR3-IGF-1/mL (IGF-1) or 10nM E2 (E2) +/- 
20nM G15 or G36. Bars with different letters are significantly different from each other 
(p < 0.05).  Data are the pooled mean ± SEM from 3 separate assays each containing 
triplicate determinations and using cells isolated from two different animals.   
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Figure 9. 
3
H-Thymidine incorporation assay showing the effects of LR3-IGF-1 (IGF-1), 
estradiol (E2), heparin binding-epidermal growth factor (hb-EGF) or fetal bovine serum 
(FBS) on proliferation in bovine satellite cell (BSC) cultures treated with a matrix 
metalloproteinase 2/9 inhibitor.  Cells were plated as detailed in Materials and Methods, 
and during the first 72 hours were grown in Dulbecco Modified Eagle Medium (DMEM) 
containing 10% FBS.  At 72 hours cultures were treated with DMEM/1%IGFBP-3-free 
swine serum (Ctrl) or DMEM/1%IGFBP-3-free swine serum plus 25ng LR3-IGF-1/mL 
(IGF-1), 10nM E2 (E2) ± 10μM MMP2/9 inhibitor (MMPI). Bars with different letters 
are significantly different (p < 0.05).  Data are the pooled mean ± SEM from 3 separate 
assays each containing triplicate determinations and using cells isolated from two 
different animals.    
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Figure 10. Proposed estrogen mechanism of action schematic as detailed in this paper 
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